How many big pharmas and what are they buyingPfizer is digesting its $43B buy of Seagen (cancer focused monoclonal antibodies). Merck bought Prometheus for $11B (immunology, non cancer, phase 3 ongoing). That leaves J&J, Amgen, Eli Lilly, Abbvie, Gilead, Novartis, Biogen, GSK, Bristol Myers Squibb , etc. I'm guessing one of them will buy Ferring before they make Adstiladrin available later this year. With BTD and AA, Theralase will have an immediate target on its back. If the limited treatments and safety aspects also qualify TLD1433 to be used as an adjuvant therapy, with say BCG or chemo, that target will be much much larger.
Question is, are these companies even aware of TLTs data? My bets would be on Novartis or Merck. If TLT shows BTD and AA. Novartis is more geared for smaller acquisitions at an advanced stage of research, per an interview I remember seeing. Good weekend, all. I'm hoping we get to hear that BTD submission is done by the AGM.